<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02034851</url>
  </required_header>
  <id_info>
    <org_study_id>IISPV_Pediatria_Dexcar</org_study_id>
    <secondary_id>2011-005805-66</secondary_id>
    <nct_id>NCT02034851</nct_id>
  </id_info>
  <brief_title>Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection</brief_title>
  <acronym>DEXCAR-0212</acronym>
  <official_title>Phase 3- Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection Episode as Renal Damage Prevention Strategy. DEXCAR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Investigacio Sanitaria Pere Virgili</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitari Sant Joan de Reus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitari Joan XXIII de Tarragona.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pius Hospital de Valls</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Arnau de Vilanova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maternal-Infantil Vall d´Hebron Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General Universitario Santa Lucía</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Rovira i Virgili</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Investigacio Sanitaria Pere Virgili</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Administration of corticoids (dexamethasone) together with the conventional
      antibiotherapy in the acute phase of a febrile urinary tract infection could reduce the risk
      of renal scarring after 6 months of the primo-infection.

      Primary objectives:To evaluate the reduction in incidence of renal scarring after 6 months of
      a acute pyelonephritis between the control group (conventional therapy plus placebo) and
      intervention group (conventional therapy plus dexamethasone.

      Design: Multicentre randomized clinical trial,placebo controled, including children between 2
      months and 14 years with a acute pyelonephritis proven by a acute phase DMSA
      (dimethylsuccinic acid ). A total of 180 children in to parallel groups (intervention and
      placebo) will be included.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The urinary tract infection (UTI) is one of the most common bacterial infections in children.
      These infections can be grouped clinically as asymptomatic bacteriuria , cystitis (lower
      urinary tract infection ) and acute pyelonephritis (APN ) when the infection reaches the
      upper urinary tract. This classification is of great clinical relevance because while
      cystitis is usually a benign condition without further complications , the APN is associated
      with an increased risk of kidney damage, acquired through renal scarring . Renal scarring is
      a consequence of the inflammatory and immune response that is triggered to eradicate the
      bacteria involved in the UTI. Parenchymal infection can be solved , but there are a number of
      poorly understood factors that may perpetuate inflammation and this would promote the
      formation of scar nephritis. One of the most relevant factors involved in the renal scarring
      development are the production of inflammatory mediators (complement proteins, bactericidal
      peptides, cytokines such as IL6 and IL8, chemokines, and adhesion molecules defensins). Thus,
      it is obvious to think that the use of anti-inflammatory drugs may prevent the release of
      these mediators and the development of permanent kidney damage.

      Intervention: the two parallel groups will receive the conventional therapy plus:

        1. dexamethasone: 0'30 mg per kg every 12 hours during 3 days.

        2. placebo (physiological saline)at the same dosing regimen.

      Centralized lecture of the late DMSA after 6 months of the pyelonephritis episode will be
      performed. Renal scarring presence and grade will be reported.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>renal scarring</measure>
    <time_frame>6 month after the acute pyelonephritis episode</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Acute Pyelonephritis</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <description>Intervention group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Placebo group (physiological saline)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Those children between 2 months and 14 years with a provable acute pyelonephritis that
        fulfill the hospitalization criteria defined in the Spanish Clinical practice guide.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Those children between 2 months and 14 years with a provable acute pyelonephritis that
        fulfill the hospitalization criteria defined in the Spanish Clinical practice guide.
        Briefly:

          -  age under 3 months.

          -  general affectation, toxic appearance.

          -  vomiting or oral intolerance.

          -  dehydration, bad peripheric perfusion.

          -  or other intermedia situations that include:

               1. high fever (&gt;38.5 Celsius) in 3-6 month old children.

               2. unusual germ risk factors.

               3. family history of vesicoureteral reflux.

               4. recurrent febrile urinary infections. With absence of a previous renal scarring
                  objectivated after a DMSA.

               5. high elevation of acute phase reactants.

        Exclusion Criteria:

          -  those eligible patients that do not fulfill the hospitalization criteria.

          -  patients with a procalcitonin under 0.05 ng per ml.

          -  patients with previous uropathy or renal scarring

          -  patients allergic to dexamethasone.

          -  endocrinologic disease.

          -  history of cancer.

          -  serious illness.

          -  immunosuppressor treatment.

          -  previous treatment with corticoids (continuous oral or parenteral treatment) during
             the last 2 months.

          -  the patient included in the study that do not present pyelonephritis after the acute
             phase DMSA evaluation will be excluded.

          -  the patient included in the study that suffered a second pyelonephritis episode during
             the following 6 months (before the second DMSA evaluation) will be excluded for the
             primary output analyses.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Escribano J Joaquin, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IISPV- URV-Hospital Universitari Sant Joan de Reus- Research unit in pediatrics, nutrition and human development</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Closa R Ricardo, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IISPV-URV- Hospital Universitari Joan XXIII de Tarragona-Research unit in pediatrics, nutrition and human development</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ferré N Natalia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IISPV-URV-Research unit in pediatrics, nutrition and human development</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ibars Z Zaira, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>HOSPITAL ARNAU DE VILANOVA DE LLEIDA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Gloria MG Fraga, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>HOSPITAL DE LA SANTA CREU I SANT PAU, DE BARCELONA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Madrid A Alvaro, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>HOSPITAL MATERNOINFANTIL VALL D'HBRON, BARCELONA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samper M Manuel, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pius Hospital de Valls</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gonzalez JD Juan David, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>HOSPITAL GENERAL UNIVERSITARIO SANTA LUCÍA DE CARTAGENA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Parada E Esther, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>HOSPITAL JOAN XXII DE TARRAGONA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Escribano J Joaquin, PhD MD</last_name>
    <phone>+34977759364</phone>
    <email>pediatria@iispv.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ferre N Natalia, PhD</last_name>
    <phone>+34977759364</phone>
    <email>natalia.ferre@urv.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General Universitario Santa Lucía de Cartagena</name>
      <address>
        <city>Cartagena</city>
        <state>Murica</state>
        <zip>E30202</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gonzalez JD Juan David, MD PhD</last_name>
      <phone>+34629684560</phone>
      <email>juand.gonzalez2@carm.es</email>
    </contact>
    <investigator>
      <last_name>Gonzalez JD Juan David, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iispv- Hospital Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>E43204</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Pius Hospital de Valls</name>
      <address>
        <city>Valls</city>
        <state>Tarragona</state>
        <zip>E43800</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samper MA Manuel Andres, MD PhD</last_name>
      <phone>977392065</phone>
      <email>msamper@piushospital.cat</email>
    </contact>
    <investigator>
      <last_name>Samper MA Manuel Andres, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Maternoinfantil Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>E08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madrid AD Alvaro Domingo, MD PhD</last_name>
      <phone>+34934893082</phone>
      <email>amadrid@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Madrid AD Alvaro Domingo, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu I Sant Pau de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>E08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fraga MG Maria Gloria, MD PhD</last_name>
      <phone>+34935537075</phone>
      <email>gfraga@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Fraga MG Maria Gloria, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <zip>E25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ibars Z Zaira, MD PhD</last_name>
      <phone>+34655462300</phone>
      <email>zairaibars@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ibars Z Zaira, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iispv-Hospital Joan Xxii de Tarragona</name>
      <address>
        <city>Tarragona</city>
        <zip>E43007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Closa R Ricardo, MD PhD</last_name>
      <phone>+34977295821</phone>
      <phone_ext>1463</phone_ext>
      <email>pediatria@iispv.cat</email>
    </contact>
    <contact_backup>
      <last_name>Closa R Ricardo, MD PhD</last_name>
      <phone>+34977759365</phone>
      <email>pediatria@iispv.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Closa R Ricardo, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Parada E Esther, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2014</study_first_submitted>
  <study_first_submitted_qc>January 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2014</study_first_posted>
  <last_update_submitted>November 24, 2015</last_update_submitted>
  <last_update_submitted_qc>November 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute pyelonephritis</keyword>
  <keyword>Renal scarring</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Children</keyword>
  <keyword>Corticoids</keyword>
  <keyword>Complementary treatment</keyword>
  <keyword>Prevention strategy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Pyelonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

